Redeye: Cinclus Pharma (Q3 review) - Pivotal studies underway
20 november, 15:19
20 november, 15:19
Redeye provides a research update following the Q3 report published by Cinclus earlier today. The financials in the report did not contain any major surprises. Instead, the headline for the quarter is the initiation of the company’s pivotal phase III study. With recruitment in full swing, we await topline results anticipated in H2 2026e.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
20 november, 15:19
Redeye provides a research update following the Q3 report published by Cinclus earlier today. The financials in the report did not contain any major surprises. Instead, the headline for the quarter is the initiation of the company’s pivotal phase III study. With recruitment in full swing, we await topline results anticipated in H2 2026e.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
BNP

Månadens mest köpta och sålda
Aktieråd

Saab
Analyser

ISK

Månadens mest köpta och sålda
Aktieråd

Saab
Analyser

ISK
1 DAG %
Senast



USA-börserna
28 november, 14:57
Wall Street ser ut att stiga inför fredagens halvdag
Ryssland
28 november, 14:35
Uppgifter: USA kan erkänna Krim som ryskt
OMX Stockholm 30
1 DAG %
Senast
2 787,77